Roivant Sciences Ltd (NASDAQ: ROIV): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. The stock was recently discussed on Yahoo Finance as it revealed that Roivant to Report Financial Results for the Third Quarter Ended December 31, 2023, and Provide Business Update on Tuesday, February 13, 2024.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.

Stocks Info

ROIV belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $10.39 and fluctuated between $10.48 as its day high and $10.26 as its day low. The current market capitalization of Roivant Sciences Ltd is $8.35B. A total of 4.64 million shares were traded on the day, compared to an average of 5.32M shares.

In the most recent transaction, Ramaswamy Vivek sold 3,000,000 shares of ROIV for 11.05 per share on Jan 02. After the transaction, the 10% Owner now owns 51,929,426 company shares. In a previous transaction on Oct 05, Venker Eric sold 153,027 shares at 10.11 per share. ROIV shares that Chief Operating Officer owns now total 595,397.

Among the insiders who sold shares, Venker Eric disposed of 606,221 shares on Oct 03 at a per-share price of $10.25. This resulted in the Chief Operating Officer holding 595,397 shares of ROIV after the transaction. In another insider transaction, Roivant Sciences Ltd. bought 1,526,316 shares at $38.00 per share on Oct 02. Company shares held by the Director now total 79,805,331.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for ROIV in the last 3 months, the mean price target is $16.20 with high estimates of $23.00 and low estimates of $12.00. In terms of 52-week highs and lows, ROIV has a high of $13.24 and a low of $6.59.

As of this writing, ROIV has an earnings estimate of -$0.32 per share for the current quarter. EPS was calculated based on a consensus of 7 estimates, with a high estimate of -$0.26 per share and a lower estimate of -$0.38. The company reported an EPS of -$0.38 in the last quarter, which was -26.70% lower than expectations of -$0.3.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. ROIV’s latest balance sheet shows that the firm has $2.06B in Cash & Short Term Investments as of fiscal 2022. There were $283.89M in debt and $184.37M in liabilities at the time. Its Book Value Per Share was $1.18, while its Total Shareholder’s Equity was $2.06B.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ROIV is Buy with a score of 4.83.

Most Popular

Related Posts